Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study- Cash burn of $4.2 million in Q3 remains in line with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback